Clinical Trial Search

Primary: Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26 — -1.114; 0.029 log (uPCR) — p=<0.0001

Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events

Primary: Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) — 0.55 ratio — p=0.0003

Primary: Change From Baseline to Week 26 in the C3G Histologic Index for Disease Activity - Subjects With Elevated C5b-9 — -0.9; -1.0 score on a scale — p=0.9670

Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants

Primary: Change From Baseline In Composite Biopsy Score At Week 28 — 11.7; 9.3; 9.2; 10.7 score on a scale

Primary: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy — 31; 68 Participants — p=<0.0001

Primary: Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15 — 0.32; 0.56; 0.48; 0.35 g/L

Primary: Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12 — 50.0; 33.3 Percentage of participants

Primary: Renal Allograft Survival Measured by Severe and Refractory Antibody Mediated Renal (AMR) — 1 Participants

Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio

Primary: Percentage of Complete Remission — 4; 3 Participants

Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…

Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072

Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day

Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio

Primary: Change in Slope of First Morning Urinary PCR From the 8-week RAAS Blocker run-in Period to the 12-week CCX168 Treatment Period — -2.4; 15.3; -23.9 mg/g/week — p=0.965

Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants

Primary: Number of Patients Enrolled With Serum Creatinine >3mg/dL on Postoperative Day 5. — 29; 32 Participants

Primary: Remission Status — 39; 13 Participants — p=0.001

Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03

Primary: Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52 — 26.4; 30.6; 30.6; 15.3…

Primary: Change From Baseline in UPCR at Week 12 — 0.83; 1.02; 1.12; 0.87 g protein/g creatinine — p=0.1924

Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7

Primary: Change in Proteinuria — 4.56; 1.36 ratio

Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg

Primary: Number of Patients With Independent Renal Function at 6 Months — 5; 5; 10 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 33; 18; 6; 3 Participants

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection